deprioritization
iTeos Therapeutics Deprioritizes Inupadenant Despite Encouraging Phase 2 Data in NSCLC
iTeos Therapeutics, Inupadenant, Adenosine A2A Receptor Antagonist, NSCLC, Phase 2 Trial, Deprioritization
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
Sanofi Deprioritizes Four Assets, Including Mid-Stage Dwarfism Treatment
Sanofi, dwarfism, mid-stage treatment, asset deprioritization, rare disease, achondroplasia